Maria Mavilio
Overview
Explore the profile of Maria Mavilio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decreased circulating IPA levels identify subjects with metabolic comorbidities: A multi-omics study
Ballanti M, Antonetti L, Mavilio M, Casagrande V, Moscatelli A, Pietrucci D, et al.
Pharmacol Res
. 2024 May;
204:107207.
PMID: 38734193
In recent years several experimental observations demonstrated that the gut microbiome plays a role in regulating positively or negatively metabolic homeostasis. Indole-3-propionic acid (IPA), a Tryptophan catabolic product mainly produced...
2.
Rizza S, Luzi A, Mavilio M, Ballanti M, Massimi A, Porzio O, et al.
Acta Diabetol
. 2022 Aug;
59(12):1589-1596.
PMID: 36044097
Aims: Disturbances in circadian rhythms may promote cardiometabolic disorders in rotating night shift workers (r-NSWs). We hypothesized that timed light therapy might reverse disrupted circadian rhythms and glucose intolerance observed...
3.
Menghini R, Hoyles L, Cardellini M, Casagrande V, Marino A, Gentileschi P, et al.
Mol Metab
. 2022 Feb;
59:101454.
PMID: 35150905
Metabolic syndrome, obesity, and steatosis are characterized by a range of dysregulations including defects in ubiquitin ligase tagging proteins for degradation. The identification of novel hepatic genes associated with fatty...
4.
Rizza S, Piciucchi G, Mavilio M, Longo S, Montagna M, Tatonetti R, et al.
Biomed Pharmacother
. 2021 Oct;
144:112341.
PMID: 34678725
Older people with type 2 diabetes (T2D) often have several comorbidities and take multiple drugs. This study tested a deprescribing strategy in older T2D patients, replacing a hypoglycemic therapeutic scheme...
5.
Rizza S, Morabito P, De Meo L, Farcomeni A, Testorio G, Cardellini M, et al.
Aging Dis
. 2021 Apr;
12(2):353-359.
PMID: 33815869
The multidimensional prognostic index (MPI) is a sensitive and specific prognosis estimation tool that accurately predicts all-cause mortality in frail older patients. It has been validated to assess the risk...
6.
Rizza S, Luzi A, Mavilio M, Ballanti M, Massimi A, Porzio O, et al.
Acta Diabetol
. 2021 Mar;
58(8):1111-1117.
PMID: 33788000
Objective: To detect premature gluco-metabolic defects among night shift workers with disturbances in circadian rhythms. Design And Methods: We performed a hypothesis-generating, cross-sectional analysis of anthropometric, metabolic, lipid, and inflammation...
7.
Rizza S, Longo S, Piciucchi G, Romanello D, Mavilio M, Montagna M, et al.
Nutr Metab Cardiovasc Dis
. 2020 Jul;
30(10):1826-1832.
PMID: 32665209
Background And Aims: Sleep disturbances may promote glucose abnormalities and inflammatory burden among shift workers. Therefore, precocious subclinical atherosclerotic process might develop in healthy shift workers even without known metabolic...
8.
Kappel B, De Angelis L, Heiser M, Ballanti M, Stoehr R, Goettsch C, et al.
Mol Metab
. 2020 Apr;
36:100976.
PMID: 32251665
Objective: The metabolic influence of gut microbiota plays a pivotal role in the pathogenesis of cardiometabolic diseases. Antibiotics affect intestinal bacterial diversity, and long-term usage has been identified as an...
9.
Menghini R, Casagrande V, Iuliani G, Rizza S, Mavilio M, Cardellini M, et al.
Int J Biochem Cell Biol
. 2019 Nov;
118:105659.
PMID: 31765819
The O subfamily of forkhead (FoxO) 1 is a crucial regulator of cell metabolism in several tissues, including the heart, where it is involved in cardiac regulation of glucose and...
10.
Casagrande V, Mauriello A, Anemona L, Mavilio M, Iuliani G, De Angelis L, et al.
Acta Diabetol
. 2019 Jul;
56(12):1265-1274.
PMID: 31292722
Aim: Obesity and low-grade inflammation are associated with an increased risk of hepatocellular carcinoma (HCC), a leading cause of cancer-related death worldwide. The tissue inhibitor of metalloproteinase (TIMP) 3, an...